- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Ali McBride, PharmD, MS, BCPS: Pharmacists' Educational Needs on Biosimilars
Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses pharmacists' educational needs on biosimilars.
Transcript:
I think it's not just pharmacists. It's the overall healthcare team and provider team. Right now I think we're still in a new and emerging area. Hopefully, shortly we’ll also see biosimilar insulin on the market, too, and that’ll be a great discussion; that’s a big topic right now in the biosimilar area.
For pharmacists, I think there needs to be a lot more discussion on how drugs are getting approved, what is the regulatory process: phase 1, phase 3. We also need to go over and delineate a lot more discussion on the global implementation of biosimilars to help provide more of a foundation for discussions here in the [United States, US].
Other areas which are requiring a lot more education: [continuing education, CE], review articles as well to get the information out there in the next few years. We need more discussion on [pharmacy and therapeutics, P and T] implementation, how that works. Reimbursement is going to be critical in this area, and there is a pure lack of understanding of reimbursement.
In fact, if there's one thing that can be done, it’s to create a level playing field for the understanding of reimbursement, both from a private payer and also government payer type of situation to make sure everyone is on the same page. I feel the more we talk about this, the more the education goes on on this, it will only help better provide resources for patients, but also institutions. So pharmacists really need to be aware of that as well.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
